Vertran, 24 mg tablets 30 pcs

Pharmacodynamics

An agonist of H1-histamine receptors of the inner ear vessels and an antagonist of H3-histamine receptors of the vestibular nuclei of the central nervous system (CNS).

Does not affect H2-histamine receptors, which improves blood flow in the vasculature of the inner ear through a relaxing effect on the pre-capillary sphincters of the cochlea and labyrinth. Relieves symptoms in Meniere’s syndrome and vertigo.

Pharmacokinetics

In oral administration, it is rapidly and completely absorbed in the gastrointestinal tract. Binding to plasma proteins is low (less than 5%). The maximum concentration in plasma (Cmax) is reached after 1 hour.

When the drug is taken with food the maximum concentration of the drug in blood is lower than when taken on an empty stomach, however, the total absorption of betahistine is the same in both cases, indicating that food intake only slows absorption of betahistine.

It is metabolized in the liver to form the inactive metabolite 2-pyridylacetic acid. Almost completely (90.7%) is excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours. The elimination rate remains constant, indicating the linearity of the pharmacokinetics of betahistine.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

In vivo studies to study the interaction with other medicinal products have not been conducted. Based on in vitro data, it can be assumed that there is no inhibition of cytochrome P450 isoenzyme activity.

In concomitant use with H1-histamine receptor blockers the therapeutic effect of betahistine may decrease.

.

Special Instructions

Contraindications

Hypersensitivity to any of the ingredients of the drug. Due to insufficient data on efficacy and safety: Pregnancy and lactation; age under 18 years.

With caution

Betahistine should be used with caution when treating patients with a history of gastric and duodenal ulcer disease. Patients with pheochromocytoma and bronchial asthma should be regularly monitored by a physician during treatment.

Side effects

Overdose

Symptoms: Mild to moderate symptoms (nausea, drowsiness, abdominal pain) may occur after dosing up to 640 mg.

More serious complications (e.g., seizures, cardiopulmonary complications) may occur with higher doses of betahistine, especially in combination with other medications.

Treatment: symptomatic.

Patients with pheochromocytoma should use the drug under medical supervision.

Pregnancy use

Similarities